Cargando…

Determinants of the Cancer Drug Funding Process in Canada

Background: Canada has a publicly funded healthcare system with a complex drug funding process. After Health Canada approval to market a drug, the pan-Canadian Oncology Drug Review (pCODR) (now renamed the CADTH reimbursement review) makes a non-binding funding recommendation to the Canadian provinc...

Descripción completa

Detalles Bibliográficos
Autores principales: Gotfrit, Joanna, Jackson, Ashley, Shin, John J. W., Stewart, David J., Mallick, Ranjeeta, Wheatley-Price, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946987/
https://www.ncbi.nlm.nih.gov/pubmed/35323362
http://dx.doi.org/10.3390/curroncol29030162
_version_ 1784674331408728064
author Gotfrit, Joanna
Jackson, Ashley
Shin, John J. W.
Stewart, David J.
Mallick, Ranjeeta
Wheatley-Price, Paul
author_facet Gotfrit, Joanna
Jackson, Ashley
Shin, John J. W.
Stewart, David J.
Mallick, Ranjeeta
Wheatley-Price, Paul
author_sort Gotfrit, Joanna
collection PubMed
description Background: Canada has a publicly funded healthcare system with a complex drug funding process. After Health Canada approval to market a drug, the pan-Canadian Oncology Drug Review (pCODR) (now renamed the CADTH reimbursement review) makes a non-binding funding recommendation to the Canadian provinces (except Quebec), which each then decide whether the drug will be publicly funded. We identified the determinants of funding in this process. Methods: We analyzed drugs for advanced lung (n = 15), breast (n = 8), colorectal (CRC) (n = 7), melanoma (n = 10), and neuroendocrine (NET) (n = 3) cancers undergoing the funding decision process from 2011 to 2019. Determinants of funding assessed in the model included list price, cancer type, drug class, and pCODR recommendation. The primary outcome was the correlation between list price and time to funding (TTF: Health Canada approval to first provincial funding). Secondary outcomes included an exploratory analysis of predictors of drug funding. Results: We analyzed 43 drugs: targeted agents 72%, immunotherapy 20%, chemotherapy 7%. A total of 72% were funded in at least one province. Median TTF was 379 days (IQR 203–601). Median list price (28-day course) was CAD 8213 (IQR CAD 5391–9445). Higher list price was not correlated with TTF (correlation coefficient −0.20, p = 0.28). There was no association between list price and pCODR recommendation or the decision to fund in at least one province. A positive pCODR recommendation correlated with the provinces’ funding decisions (p < 0.001), where 89% of drugs with a positive recommendation were funded and 100% of drugs with a negative recommendation were not funded. Tumor type was predictive of TTF (p < 0.001): CRC drugs were the slowest at a median of 2541 days (IQR 702–4379), and NETs were the quickest at a median of 0 days (IQR 0–502). Cancer type predicted decision to fund in at least one province (p = 0.005), with funding for 100% of NET drugs at the high end and 29% of CRC drugs at the low end. Drug class was predictive of TTF (p = 0.01): 465 days (IQR 245–702) for targeted agents, 443 days (IQR 298–587) for chemotherapy, and 339 days (IQR 164–446) for immunotherapy. Conclusions: Determinants of drug funding included cancer type, drug class, and pCODR recommendation but not list price. Factors other than cost were more heavily weighted in the funding decisions of cancer drugs in Canadian provinces.
format Online
Article
Text
id pubmed-8946987
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89469872022-03-25 Determinants of the Cancer Drug Funding Process in Canada Gotfrit, Joanna Jackson, Ashley Shin, John J. W. Stewart, David J. Mallick, Ranjeeta Wheatley-Price, Paul Curr Oncol Article Background: Canada has a publicly funded healthcare system with a complex drug funding process. After Health Canada approval to market a drug, the pan-Canadian Oncology Drug Review (pCODR) (now renamed the CADTH reimbursement review) makes a non-binding funding recommendation to the Canadian provinces (except Quebec), which each then decide whether the drug will be publicly funded. We identified the determinants of funding in this process. Methods: We analyzed drugs for advanced lung (n = 15), breast (n = 8), colorectal (CRC) (n = 7), melanoma (n = 10), and neuroendocrine (NET) (n = 3) cancers undergoing the funding decision process from 2011 to 2019. Determinants of funding assessed in the model included list price, cancer type, drug class, and pCODR recommendation. The primary outcome was the correlation between list price and time to funding (TTF: Health Canada approval to first provincial funding). Secondary outcomes included an exploratory analysis of predictors of drug funding. Results: We analyzed 43 drugs: targeted agents 72%, immunotherapy 20%, chemotherapy 7%. A total of 72% were funded in at least one province. Median TTF was 379 days (IQR 203–601). Median list price (28-day course) was CAD 8213 (IQR CAD 5391–9445). Higher list price was not correlated with TTF (correlation coefficient −0.20, p = 0.28). There was no association between list price and pCODR recommendation or the decision to fund in at least one province. A positive pCODR recommendation correlated with the provinces’ funding decisions (p < 0.001), where 89% of drugs with a positive recommendation were funded and 100% of drugs with a negative recommendation were not funded. Tumor type was predictive of TTF (p < 0.001): CRC drugs were the slowest at a median of 2541 days (IQR 702–4379), and NETs were the quickest at a median of 0 days (IQR 0–502). Cancer type predicted decision to fund in at least one province (p = 0.005), with funding for 100% of NET drugs at the high end and 29% of CRC drugs at the low end. Drug class was predictive of TTF (p = 0.01): 465 days (IQR 245–702) for targeted agents, 443 days (IQR 298–587) for chemotherapy, and 339 days (IQR 164–446) for immunotherapy. Conclusions: Determinants of drug funding included cancer type, drug class, and pCODR recommendation but not list price. Factors other than cost were more heavily weighted in the funding decisions of cancer drugs in Canadian provinces. MDPI 2022-03-15 /pmc/articles/PMC8946987/ /pubmed/35323362 http://dx.doi.org/10.3390/curroncol29030162 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gotfrit, Joanna
Jackson, Ashley
Shin, John J. W.
Stewart, David J.
Mallick, Ranjeeta
Wheatley-Price, Paul
Determinants of the Cancer Drug Funding Process in Canada
title Determinants of the Cancer Drug Funding Process in Canada
title_full Determinants of the Cancer Drug Funding Process in Canada
title_fullStr Determinants of the Cancer Drug Funding Process in Canada
title_full_unstemmed Determinants of the Cancer Drug Funding Process in Canada
title_short Determinants of the Cancer Drug Funding Process in Canada
title_sort determinants of the cancer drug funding process in canada
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946987/
https://www.ncbi.nlm.nih.gov/pubmed/35323362
http://dx.doi.org/10.3390/curroncol29030162
work_keys_str_mv AT gotfritjoanna determinantsofthecancerdrugfundingprocessincanada
AT jacksonashley determinantsofthecancerdrugfundingprocessincanada
AT shinjohnjw determinantsofthecancerdrugfundingprocessincanada
AT stewartdavidj determinantsofthecancerdrugfundingprocessincanada
AT mallickranjeeta determinantsofthecancerdrugfundingprocessincanada
AT wheatleypricepaul determinantsofthecancerdrugfundingprocessincanada